In this interview, Uma Kativa explains the mechanisms of lipid nanoparticles and her work as Principal Scientist at Bristol Myers Squibb (NJ, USA). She discusses the bioanalysis of lipid nanoparticle products and the importance of assessing immunogenicity, as well as some of the challenges with regulatory guidelines and how these can be overcome.
About the author:
Uma Kativa has been a principle researcher at Bristol Myers Squibb since 2013 and has been involved with multiple aspects of their research, including molecular biology, immunology, drug development and discovery. Her interests lie in next generation drug modalities such as CAR T, bi-specifics, and viral/nano-particle mediated gene therapeutics.
Video originally published on Bioanalysis Zone, a digital platform from the Future Science Group that aims to advance the field of bioanalysis by increasing subject understanding and sharing of knowledge across barriers to unite the bioanalytical community.